Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average

From a technical perspective, Legend Biotech Corporation Sponsored ADR (LEGN) is looking like an interesting pick, as it just reached a key level of support. LEGN recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

Zacks Investment Research • 9 hours ago

Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results

BRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m.

GlobeNewsWire • Oct 27, 2026

Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors

After reaching an important support level, Legend Biotech Corporation Sponsored ADR (LEGN) could be a good stock pick from a technical perspective. LEGN surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

Zacks Investment Research • Oct 27, 2026

Legend Biotech: Carvykti Makes Billions, But The Profits Are Elusive

CARVYKTI's quarterly sales reached $710 million, but Legend's high expenses have kept recurring profitability low. Q2 results show improving operating leverage, with collaboration revenue growing faster than associated costs. I rate LEGN a cautious buy, given the commercial growth opportunity but limited margin of safety.

Seeking Alpha • Oct 22, 2026

Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance  IND clearance supports planned U.S. Phase 1/2 study and advances Legend Biotech's in vivo cell engineering platform BRIDGEWATER, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LB2501, an investigational in vivo CAR-T therapy designed to generate CD19/CD20 dual-targeting chimeric antigen receptor T (CAR-T) cells directly within the patient, for the treatment of relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma.

GlobeNewsWire • Oct 15, 2026

Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the launch of its inaugural Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program, an annual grant initiative designed to recognize and support early-career healthcare professionals advancing novel cell therapy approaches for the treatment of multiple myeloma.

GlobeNewsWire • Oct 1, 2026

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM

GlobeNewsWire • Sep 25, 2026

Legend Biotech taps Novartis veteran Zhang as CEO

Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an ​industry veteran to steer its expansion beyond blockbuster ‌cancer therapy Carvykti.

Reuters • Sep 15, 2026

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026.

GlobeNewsWire • Sep 15, 2026

Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July

Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.

WSJ • Sep 15, 2026